Asthma Inhaler Availability in Hospital Pharmacies India
Why asthma inhalers are inconsistently stocked in Indian hospital and public-sector pharmacies, and what that gap costs in outcomes.
This covers how bad asthma inhaler availability actually is across Indian public and hospital pharmacies, what the government's own essential medicines policy says versus what's found on the ground, why inhaled corticosteroid underuse specifically matters, and what a hospital pharmacy should do differently.
How available are asthma inhalers in Indian public health facilities?
Availability varies enormously by state and by whether the product is an innovator brand or a generic. Published facility-survey research found generic salbutamol inhaler availability ranging from 83% to 100% across the states studied, while innovator-brand availability ranged from just 20% to 95%, with actual public-sector stocking far below what national policy calls for.
The Ministry of Health and Family Welfare has designated salbutamol, beclomethasone and budesonide inhalers as essential asthma medicines meant to be available at every level of public care, from primary through tertiary. In practice, researchers found these medicines absent from almost all public health centres surveyed, with only isolated exceptions such as a single government hospital in Jaipur showing consistent stock of both salbutamol and beclomethasone.
Why does inhaled corticosteroid underuse matter so much for outcomes?
Inhaled corticosteroids are the guideline-recommended controller therapy that prevents the airway inflammation underlying asthma attacks, as distinct from a reliever inhaler like salbutamol that only treats an attack already underway. Published research specifically connects India's underuse of inhaled corticosteroids to the country's outsized share of global asthma mortality, at roughly 42% of asthma deaths worldwide.
That is a control-therapy gap, not a rescue-therapy gap. A patient who can access a salbutamol inhaler during an attack but never gets consistent access to a controller inhaler between attacks remains at elevated risk of the exact severe exacerbations that drive mortality, which is precisely the pattern the underuse research describes.
Is the gap about price, availability, or both?
Both, and they compound each other. Facility surveys measuring price, availability and affordability of essential medicines together, including a Delhi-specific assessment ahead of the state's free-medicine rollout, found that even where an inhaler was priced reasonably, it frequently wasn't stocked at the public facility a patient could actually reach, while private retail pharmacies carried better stock at a price many patients couldn't sustain long-term.
This dual failure explains why price control alone, without a parallel fix to public-sector distribution reliability, hasn't closed the gap. A ceiling price on an inhaler that a facility doesn't stock protects nobody, and a well-stocked private pharmacy a patient can't afford protects nobody either.
What does this mean for a hospital's own pharmacy, beyond the public system?
A hospital pharmacy sits in a different position than a primary health centre, but the underlying lesson transfers directly. Reliever and controller inhalers need tracking and reordering as two functionally distinct categories, not one undifferentiated "asthma inhaler" line.
Running short on a reliever inhaler is an acute safety problem. Running short on a controller inhaler is a slower-building risk, one that shows up later as more frequent exacerbations and hospital readmissions.
A hospital's own asthma readmission data is a better forecasting input for controller inhaler stock than a generic essential-medicines checklist, since the national data shows exactly this category is the one most likely to be under-stocked relative to policy intent.
Why does this matter for hospital revenue and continuity of care, not just public health policy?
When a hospital's own pharmacy doesn't reliably carry a patient's controller inhaler, that patient either goes without it or sources it from an outside chemist who may face the identical stock gap the national surveys describe. Either outcome raises the odds of a future exacerbation landing back at the same hospital as an emergency admission, at a far higher cost than the inhaler itself would have carried.
Our managed hospital pharmacy services guide covers how reliable in-house stocking of both reliever and controller inhalers keeps a respiratory patient's prescription inside the hospital instead of leaking to an outside chemist with the same availability problem, and our prescription leakage piece covers what that gap costs a hospital in lost continuity and lost revenue.
Sources
- 1Is underuse of Inhaled Corticosteroids for Asthma in India contributing to 42% of global asthma deaths? — National Institutes of Health, National Library of Medicine
- 2Availability, price and affordability of asthma medicines in five Indian states — National Institutes of Health, National Library of Medicine, PubMed
- 3Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all — National Institutes of Health, National Library of Medicine, BMC Health Services Research
- 4The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review — National Institutes of Health, National Library of Medicine, The Lancet Global Health
- 5National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
This article is for informational purposes and is not a substitute for professional medical advice. Inhaler choice and asthma management are clinical decisions made by the treating physician based on the individual patient; this article does not recommend a specific treatment for any individual case.
FAQ
Frequently asked questions
Availability is inconsistent and often poor. One state-level survey found salbutamol inhalers stocked in only 30% of public facilities in Rajasthan, and national research found essential asthma inhalers largely absent from public health centres despite government policy designating them essential.
Published research links India's roughly 42% share of global asthma deaths specifically to underuse of inhaled corticosteroids, the controller therapy that prevents the airway inflammation behind severe attacks, rather than to a lack of reliever inhalers alone.
Yes. Facility surveys found generic salbutamol inhaler availability running from 83% to 100% across the states studied, notably higher and more consistent than innovator-brand availability, which ranged from just 20% to 95%.
Not on its own. Research assessing price, availability and affordability together found inhalers sometimes priced reasonably but still absent from the public facility a patient could reach, showing that distribution reliability and price both need fixing together.
No. A reliever inhaler shortage is an acute safety risk, while a controller inhaler shortage is a slower-building risk tied to future exacerbations and readmissions, so the two need separate reorder logic rather than one combined "asthma inhaler" stocking rule.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.